Bluebird Bio Signs a Three-Year Research Collaboration with Novo Nordisk to Develop In-Vivo Genome Editing Therapies for Hemophilia A

Bluebird Bio’s Zynteglo Receives CHMP’s Positive Opinion for Conditional Marketing for Patients with Transfusion-Dependent β-Thalassemia (TDT) without β0/β0 Genotype


  • Bluebird Bio to utilize its mRNA-based megaTAL technology providing a specific and efficient way to silence, edit or insert genetic components combining Novo Nordisk’s deep expertise in hemophilia research and therapeutics 
  • The focus of the collaboration is to identify gene therapy candidates for people with severe genetic diseases with initial interest of correcting FVIII-clotting factor deficiency providing lifetime free of factor replacement therapy
  • MegaTALs are single-chain fusion enzyme that combines to DNA cleaving processes of Homing Endonucleases (HEs) with the DNA binding region of transcription activator-like (TAL) effectors

Click here to­ read full press release/ article | Ref: Bluebird Bio | Image: Twitter